Scaling CRISPR For Rare Disease With Aurora Therapeutics' Dr. Edward Kaye

Gene Editing Has Struggled To Go Commercial. This Nobel Laureate Has A $1 Billion Plan To Fix That.

Biotech CEOs discuss the state of the industry, what is needed to compete globally, the importance of having a patient-centric approach, and more

JPM 2026: Aurora Therapeutics’ Edward Kaye on Scalable Personalized Gene Editing

Aurora sets out to capitalize on FDA’s new framework for bespoke drug therapies

Key scientist from Baby KJ team launches startup to scale personalized CRISPR medicines

Crispr Pioneer Launches Startup to Make Tailored Gene-Editing Treatments

Gene editing pioneers launch first startup focused on custom CRISPR therapies